Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 511

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 511
---
HURA by increasing its cost of labor and research and development contract costs. TuHURA does not believe inflation has had a material effect on its results of operations during the periods presented.**

<div align='center'>316</div>

TUHURA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE Management and the Board of Directors The following table sets forth the persons who serve as TuHURA’s executive officers and directors, and their ages as of March 31, 2025:

| Name                                  |     |   Age |     | Position(s)                          |
| Executive Officers                    |     |       |     |                                      |
| James Bianco, M.D.                    |     |    68 |     | Chief Executive Officer and Director |
| Dan Dearborn                          |     |    58 |     | Chief Financial Officer              |
| Non-Employee Directors                |     |       |     |                                      |
| James Manuso, Ph.D., MBA              |     |    76 |     | Director and Chairman of the Board   |
| Alan List, M.D.                       |     |    70 |     | Director                             |
| George Ng                             |     |    51 |     | Director                             |
| Robert E. Hoffman Craig Tendler, M.D. |     | 59 66 |     | Director Director                    |

**Executive Officers James Bianco, M.D.has served as Legacy TuHURA’s Chief Executive Officer and as a director of Legacy TuHURA since July 1, 2021, and was appointed Chief Executive Officer of TuHURA and a director on the TuHURA Board of Directors following the completion of the Kintara Merger. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of Morphogenesis Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to TuHURA. Dr. Bianco is a 30-year veteran of the biopharmaceutical industry. In 1991, Dr. Bianco founded CTI Biopharma, Inc. (“CTI”) and from 1992 to 2016 was the Chief Executive Officer of CTI. During his tenure at CTI, Dr. Bianco was responsible for strategic portfolio development and identifying, acquiring, licensing, purchasing, or acquiring through international merger and acquisition, five drug candidates, four of which have since been approved by the FDA and with three